Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial

Simple item page
dc.contributor.authorDragsted, Ulrik Bak
dc.contributor.authorGerstoft, Jan
dc.contributor.authorPedersen, Court
dc.contributor.authorPeters, Barry
dc.contributor.authorDuran, Adriana
dc.contributor.authorObel, Niels
dc.contributor.authorCastagna, Antonella
dc.contributor.authorCahn, Pedro
dc.contributor.authorClumeck, Nathan
dc.contributor.authorBruun, Johan N
dc.contributor.authorBenetucci, Jorge
dc.contributor.authorHill, Andrew
dc.contributor.authorCassetti, Isabel
dc.contributor.authorVernazza, Pietro
dc.contributor.authorYoule, Mike
dc.contributor.authorFox, Zoe
dc.contributor.authorMaxCmin1 Trial Group
dc.date.accessioned2024-05-23T23:49:29Z
dc.date.available2024-05-23T23:49:29Z
dc.date.issued2003-09-01
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractThis trial assessed the rate of virological failure at 48 weeks in adult human immunodeficiency virus (HIV) type 1–infected patients assigned indinavir/ritonavir (Idv/Rtv; 800/100 mg 2 times daily) or saquinavir/ritonavir (Sqv/Rtv; 1000/100 mg 2 times daily) in an open-label, randomized (1:1), multicenter, phase 4 design. Three hundred six patients began the assigned treatment. At 48 weeks, virological failure was seen in 43 (27%) of 158 and 37 (25%) of 148 patients in the Idv/Rtv and Sqv/Rtv arms, respectively. The time to virological failure did not differ between study arms (P=.76). When switching from randomized treatment was counted as failure, this was seen in 78 of 158 patients in the Idv/Rtv arm, versus 51 of 148 patients in the Sqv/Rtv arm (P=.009). A switch from the randomized treatment occurred in 64 (41%) of 158 patients in the Idv/Rtv arm, versus 40 (27%) of 148 patients in the Sqv/Rtv arm (P=.013). Sixty-four percent of the switches occurred because of adverse events. A greater number of treatment-limiting adverse events were observed in the Idv/Rtv arm, relative to the Sqv/Rtv arm. In conclusion, Rtv-boosed Sqv and Idv were found to have comparable antiretroviral effects in the doses studiedes_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1086/377288
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1363
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesThe Journal of Infectious Diseases;Sep 2003;188(1)635–642
dc.rightsopenAccesses_ES
dc.subjectClinical Triales_ES
dc.subjectHIV-1es_ES
dc.titleRandomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Triales_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1086-377288.pdf
Size:
227.44 KB
Format:
Adobe Portable Document Format
Description:
10.1086/377288_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos